LakeShore Biopharma Co (LakeShore Biopharma Co) EBITDA Margin % : -51.44% (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. LakeShore Biopharma Co's EBITDA for the six months ended in Sep. 2023 was $-19.25 Mil. LakeShore Biopharma Co's Revenue for the six months ended in Sep. 2023 was $37.42 Mil. Therefore, LakeShore Biopharma Co's EBITDA margin for the quarter that ended in Sep. 2023 was -51.44%.

LakeShore Biopharma Co EBITDA Margin % Historical Data

The historical data trend for LakeShore Biopharma Co's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co EBITDA Margin % Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

EBITDA Margin %

-45.43

-13.36

-11.18

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBITDA Margin %	Get a 7-Day Free Trial			-8.97	-18.43	5.48	-34.31	-51.44

Competitive Comparison of LakeShore Biopharma Co's EBITDA Margin %

For the Biotechnology subindustry, LakeShore Biopharma Co's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's EBITDA Margin % falls into.

LakeShore Biopharma Co EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

LakeShore Biopharma Co's EBITDA Margin % for the fiscal year that ended in Mar. 2023 is calculated as

EBITDA Margin %	=	EBITDA (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-11.145	/	99.726
	=	-11.18 %

LakeShore Biopharma Co's EBITDA Margin % for the quarter that ended in Sep. 2023 is calculated as

EBITDA Margin %	=	EBITDA (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-19.25	/	37.421
	=	-51.44 %

LakeShore Biopharma Co (NAS:LSB) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.

LakeShore Biopharma Co EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » EBITDA Margin %

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.